Study of new HIV injection vs. standard injectables
Treatments studied
Part of Immune system & allergy, Infections clinical trials.
This phase 3 trial tests a new long-acting, injectable two-drug combination (lenacapavir + teropavimab + zinlirvimab) vs. another injectable combo (cabotegravir + rilpivirine) for people whose HIV is already well-controlled on daily oral meds. It aims to see if the new combo can keep the virus under control with fewer injections.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your HIV must be well-controlled (undetectable viral load for at least 6 months).
- You must be on a stable daily oral HIV medicine that you haven't changed in the last 6 months.
- You cannot have had treatment failure or known resistance to certain HIV meds.
- You cannot have active infections like TB, serious liver disease, or need ongoing immune-suppressing therapy.
- You cannot have previously used the study drugs or other long-acting injectable HIV treatments.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows adults with well-controlled HIV who are planning to switch to a long-acting HIV medicine given as injections. It may help researchers understand how this approach works for people already stable on current treatment.
This trial tests a new ultra-long-acting injectable combination of cabotegravir and rilpivirine for people with HIV who already have the virus under control. It aims to see if these shots can keep the virus suppressed with fewer doses.
This study tests a new shot (called VH4011499) that may help control HIV. It is given together with another shot, cabotegravir, so you might not need to take daily pills. The study is for people who have never treated their HIV before.
This study tests a new injectable drug (VH4011499) for safety and how the body processes it. It's for healthy adults without HIV, and participants will get either the study drug or a placebo (an inactive shot).
This trial tests a new combination of three medications, lenacapavir, teropavimab, and zinlirvimab, for people with HIV who currently have undetectable virus levels on a stable oral treatment. The goal is to see if these drugs can keep the virus suppressed, possibly allowing a simpler treatment plan.
This trial tests whether switching from daily HIV pills to a long-acting injectable combination (cabotegravir and rilpivirine) is safe and effective for people whose HIV is well controlled. Instead of taking pills every day, you would receive a shot every month or two, which may be more convenient.
Hear when a new HIV Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.